Congratulations Dr Dzulkefly Ahmad, New Minister of Health Malaysia

Congratulations to Malaysia’s new Minister of Health, YB Dr Dzulkefly Ahmad!

From the Managemant and Staff of Clinical Research Malaysia.

Congratulations to Tun Dr. Mahathir, Malaysia’s New Prime Minister

Congratulations to our 7th Prime Minister of Malaysia, Y.A.B. Tun Dr Mahathir Mohamad!

Setinggi-tinggi ucapan tahniah kepada Yang Amat Berhormat Tun Dr Mahathir Mohamad, yang telah dilantik sebagai Perdana Menteri Malaysia Ke-7 yang baharu.

From the Managemant and Staff of Clinical Research Malaysia.

Hospital Miri 2nd Top Recruiter Globally for Respiratory Study

Standing L-R: Dr Tey Chin Wei, Dr Koh Huah Chian, Dr Andy Tang Sing Ong. Seating L-R: Salina, Dato’ Dr Fam Tem Lom, Dr Desmond Samuel(PI), Wan Ainor.

Congratulations Hospital Miri, Sarawak for being the 2nd Top Recruiter Globally for a respiratory study recently. The study team is lead by Principle Investigator, Dr. Desmond Samuel and supported by 2 of CRM’s study coordinators Ms. Salina Lisang and Wan Ainor. We hope for more great success story from the site. Thank you for making Malaysia proud!

Dr Chua Ee Yong, Sub-PI

Dr. Lee Ling Yuin, Sub-PI

 

Clinical Research Malaysia Forms Two Global Partnerships and New Foreign Investments

L-R: Dr. Akhmal Yusof (CEO of CRM), Mr. Zabidi Mahbar (Executive Director of Strategic Planning (Manufacturing), Malaysian Investment Development Authority (MIDA), YBhg Datuk Dr. Noor Hisham Abdullah (Director General of Health, Malaysia), Dr. Hytham Al-Masri (President & CEO of Hematogenix) and Dr. Yooni Kim (Executive Director, Asia Operations, Novotech)

PUTRAJAYA, 20 April 2018 – Hematogenix, a global leader in integrated laboratory services, and Novotech, Australia’s largest independent contract research organization (CRO) have both signed a Memorandum of Understanding with Clinical Research Malaysia (CRM) to establish strategic partnerships in clinical research.

The inking of this MoU with Hematogenix will have the potential to set Malaysia apart from its Asia counterparts as Hematogenix intends to invest in setting up its central laboratory services (that focuses on cancer related research and clinical trials) in this country. Hematogenix is only one of a handful of providers of such services in the USA and a leader in immune-oncology testing for drug development. The establishment of their central laboratory services will be the first of such kind in the Asia region and is anticipated to be the largest globally in due time, surpassing the one in Chicago. Through its Asia operations, Malaysia can expect to attract more global clinical trials into the country, upscale the Malaysian medical talents and bring in more investments into the nation’s economy.  Read more

CRM’s Pilot Training Programme: Fundamental of Clinical Research & Practice

The Fundamental of Clinical Research & Practice, it’s CRM’s pilot training programme together with C&R Research Inc. (Korea). This 3 days training are packed with all-you-need-to-know about conducting clinical trials.

In our journey to be the global preferred site for clinical trial, we will need to equip our people with global standard practice in clinical research.

This is one of many trainings that we have in the pipeline and stay tuned for more future programmes conducted by CRM.

About This Training:
The Fundamental of Clinical Research & Practice Course is an introductory training that provides the fundamental information to understand clinical research. It includes Overview of Drug Development, Non-Clinical study, Trial Phases involved and the objective of every phases. The course will also cover the most important guideline in conducting clinical research, Principles of Good Clinical Practice and brief discussion of Roles and Responsibilities of players in clinical research (Institutional Review Board/ Independent Ethics Committee, Investigators and Sponsor).

NHAM-CRM Research Track 2018

This is the 2nd NHAM-CRM Research Track organized by Clinical Research Malaysia (CRM) in collaboration with the National Heart Association of Malaysia (NHAM) and Malaysian Society Pharmacology and Physiology.

We are honoured to have with us today, Datuk Dr Shahnaz Murad (Deputy Director-General of Health (Research & Technical Support), Ministry of Health Malaysia) to officiate the NHAM-CRM Research Track at the NHAM 2018 Conference. Welcoming speech was given by Dr. Akhmal Yusof (CEO of CRM) followed by Dr Ng Wai Kiat (NHAM President).

Read more

New affordable hepatitis C combination treatment shows 97% cure rate

Healthcare worker examines liver of hepatitis C patient in Thailand

Results support a public health approach to hepatitis C

An affordable hepatitis C combination treatment including the new drug candidate ravidasvir has been shown to be safe and effective, with extremely high cure rates for patients, including hard-to-treat cases, according to interim results from the Phase II/III STORM-C-1 trial presented by the non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) at the International Liver Conference in Paris.

[Bahasa Malaysia] [Español] [Français] [Mandarin Chinese] [Português] [Tamil]

Read more

CRC-CRM Network received IQVIA Global Recognition Award

Petaling Jaya, 12 April — IQVIA presented Global Site Recognition Award, 2017 Certificate of Achivement to CRC-CRM Network at the 2018 Prime Site Joint Steering Committee Meeting earlier today. This award is only given to top-performing sites in IQVIA’s Prime and Partner program that have demonstrated excellence in clinical research performance and quality. Read more

Sultan of Johor Announces Tunku Laksamana Johor Cancer Centre

JOHOR BAHRU, Malaysia, April 2, 2018 /PRNewswire/ — His Majesty Sultan Ibrahim Ibni Almarhum Sultan Iskandar, the Sultan of Johor, announced yesterday the establishment of a regional centre for cancer treatment, research and education, led by Singapore-headquartered Asian American Medical Group (“AAMG”).

The Tunku Laksamana Johor Cancer Centre (“TLJCC”) is  slated for an end-2020 opening in Iskandar Puteri. Its first phase will offer:

i.          Diagnostics and imaging: PET/CT, CT/MRI with liquid biopsy;
ii.         Personalised oncology using gene profiling and targeted chemo/immunotherapy; and
iii.        Radiation therapy: IMRT, SBRT and VMAT. Read more

Alteogen to set up biosimilar jv in Malaysia for foray into ASEAN market

Korea’s pharmaceutical company Alteogen said on Thursday it has signed a memorandum of agreement with Malaysia’s Inno Bio Ventures to set up a joint venture for biosimilar business in the Southeast Asian country.

The joint venture will be responsible for the development, clinical research, production and marketing of biosimilar drugs. Inno Bio Ventures is a state-funded corporation founded in 2002.

Read more